| 沈延宝,赵琼琼,乔雪婷,蒙 艳,胡学甫.降脂通脉胶囊联合瑞舒伐他汀治疗冠心病合并颈动脉粥样硬化斑块的临床研究[J].,2021,(9):1763-1766 |
| 降脂通脉胶囊联合瑞舒伐他汀治疗冠心病合并颈动脉粥样硬化斑块的临床研究 |
| Clinical Study of Jiangzhitongmai Capsule Combined with Rosuvastatin in the Treatment of Coronary Heart Disease with Carotid Atherosclerotic Plaque |
| 投稿时间：2020-11-29 修订日期：2020-12-23 |
| DOI：10.13241/j.cnki.pmb.2021.09.036 |
| 中文关键词: 降脂通脉胶囊 瑞舒伐他汀 冠心病 颈动脉粥样硬化斑块 疗效 |
| 英文关键词: Jiangzhitongmai capsule Rosuvastatin Coronary heart disease Carotid atherosclerotic plaque Efficacy |
| 基金项目:青海省卫生和计划生育委员会医药卫生科技项目(2018-wjzdx-110) |
|
| 摘要点击次数: 991 |
| 全文下载次数: 596 |
| 中文摘要: |
| 摘要 目的：探讨降脂通脉胶囊联合瑞舒伐他汀治疗冠心病合并颈动脉粥样硬化斑块的临床疗效。方法：选取2018年2月~2019年10月期间我院收治的冠心病合并颈动脉粥样硬化斑块患者80例，根据随机数字表法分为对照组（n=40）和研究组（n=40），对照组患者予以瑞舒伐他汀治疗，研究组在对照组的基础上予以降脂通脉胶囊治疗，比较两组患者疗效、血脂、心功能、颈动脉内膜中层厚度（IMT）、颈动脉斑块积分及不良反应。结果：研究组治疗6个月后的临床总有效率为90.00%（36/40），高于对照组的70.00%（28/40）（P<0.05）。两组治疗6个月后心排血量（CO）、射血分数（LVEF）均较治疗前升高，且研究组高于对照组（P<0.05）；左室舒张末内径（LVEDD）较治疗前降低，且研究组低于对照组（P<0.05）。两组治疗6个月后总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）均较治疗前下降，且研究组低于对照组（P<0.05）；高密度脂蛋白胆固醇（HDL-C）较治疗前升高，且研究组高于对照组（P<0.05）。两组治疗6个月后IMT、颈动脉斑块积分均较治疗前下降，且研究组低于对照组（P<0.05）。两组均未见明显不良反应发生。结论：降脂通脉胶囊联合瑞舒伐他汀治疗冠心病合并颈动脉粥样硬化斑块，疗效显著，可有效改善患者血脂、心功能及颈动脉斑块病变，且安全可靠。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect of Jiangzhitongmai capsule combined with rosuvastatin in the treatment of coronary heart disease with carotid atherosclerotic plaque. Methods: 80 patients with coronary heart disease with carotid atherosclerotic plaque who were admitted to our hospital from February 2018 to October 2019 were selected, patients were divided into control group (n=40) and study group (n=40) according to the method of random number table. Patients in the control group were treated with rosuvastatin, while patients in the study group were treated with Jiangzhitongmai capsule on the basis of the control group. The curative effect, blood lipid, heart function, carotid intima-media thickness (IMT), carotid plaque score and adverse reactions of patients in the two groups were compared. Results: 6 months after treatment, the total clinical effective rate of the study group was 90.00%(36/40), which was higher than 70.00% (28/40) of the control group (P<0.05). 6 months after treatment, the cardiac output (CO) and ejection fraction (LVEF) of the two groups were higher than those before treatment, study group was higher control group(P<0.05). The left ventricular end diastolic diameter (LVEDD) was lower than that before treatment, study group was lower control group(P<0.05). Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) of the two groups at 6 months after treatment decreased compared with before treatment, and study group was lower than control group (P<0.05). The high-density lipoprotein cholesterol (HDL-C) was higher than before treatment, study group was higher control group(P<0.05). The scores of IMT and carotid plaque scores in the two groups at 6 months after treatment decreased compared with before treatment, and study group were lower than control group(P<0.05). No obvious adverse reactions were found in both groups. Conclusion: Jiangzhi tongmai capsule combined with rosuvastatin is effective in the treatment of coronary heart disease with carotid atherosclerotic plaques. It can effectively improve the patients' blood lipid, cardiac function and carotid artery plaque lesions, and it is safe and reliable. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
